1
Margo P Cohen: Monoclonal antibodies against glycated albumin, hybrid cell lines producing these antibodies, and use therefore. Exocell, Banner Birch McKie & Beckett, June 29, 1993: US05223392 (24 worldwide citation)

The present invention is directed to monoclonal antibodies, and hybridomas which produce them, which are preferentially reactive with glycated albumin and insignificantly reactive with other proteins, as well methods of using these monoclonal antibodies to detect glycated albumin.


2
Margo P Cohen, Clyde W Shearman: Genetically engineered immunoglobulins with specificity for glycated albumin. Exocell, Caesar Rivise Bernstein Cohen & Pokotilow, June 1, 1999: US05908925 (16 worldwide citation)

This invention deals with genetically engineered immunoglobulins with affinity and specificity for (human) glycated albumin. The invention is directed to the DNA which encodes the immunoglobulins. The DNA sequence can be manipulated to produce chimeras and fragments such as Fab, F(ab').sub.2 or ScFv ...


3
Margo P Cohen: Monoclonal antibodies against glycated low density lipoprotein. Exocell, February 27, 1996: US05494791 (11 worldwide citation)

An antibody specifically immunoreactive with glycated LDL and methods for using the antibody are provided. The antibody can be used for quantitating amounts of glycated LDL in a sample, for monitoring glycemic control in diabetic patients, for diagnosing disease, for monitoring and diagnosing athero ...


4
Margo P Cohen: Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies. Exocell, April 22, 2003: US06552077 (11 worldwide citation)

The present invention is directed to compositions that inhibit the nonenzymatic glycation of albumin, as well as methods of using compounds that inhibit albumin glycation for the treatment of glycation-related pathologies.


5
Margo P Cohen: Treatment of complications of diabetes with substances reactive with the fructosyl-lysine structure in glycated albumin. Exocell, May 21, 1996: US05518720 (8 worldwide citation)

Methods of in vivo diagnosis and treatment for complications of diabetes are provided. Antibodies or other mimetic molecules which specifically bind to glycated albumin or its cellular receptor are administered to a human. Glycated albumin which retains a deoxyfructosyllysine moiety is found deposit ...


6
Margo P Cohen: Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies. Exocell, Caesar Rivise Bernstein Cohen & Pokitilow, March 12, 2002: US06355680 (8 worldwide citation)

The present invention is directed to compositions that inhibit the nonenzymatic glycation of albumin,, as well as methods of using compounds that inhibit albumin glycation for the treatment of glycation-related pathologies.


7
Margo P Cohen, Rex Clements: In vivo methods of treatment to prevent kidney dysfunction using substances that inhibit albumin glycation. Exocell, Caesar Rivise Bernstein Cohen & Pokotilow, December 14, 1999: US06001875 (3 worldwide citation)

The present invention is directed to the prevention in vivo of the nonenzymatic glycation of albumin, which generates biologically active Amadori glucose adducts in the albumin molecule, as well as methods of using compounds that protect against nonenzymatic glycation in vivo to treat kidney dysfunc ...


8
Margo P Cohen, Rex S Clements: In Vivo Methods to reduce hypercholesterolemia and improve vascular dysfunction. Exocell, Caesar Rivise Bernstein Cohen & Pokotilow, November 30, 1999: US05994401 (2 worldwide citation)

The present invention is directed to the prevention in vivo of post-secretory Amadori modifications in the Apo B molecule, as well as methods of using compounds that protect against these modifications in vivo to treat hypercholesterolemia and vascular dysfunction.


9
Margo P Cohen, Van Yu Wu: Isolation of a soluble 42 KD pancreatic islet cell autoantigen. Exocell, Banner Birch McKie & Beckett, May 17, 1994: US05312628 (1 worldwide citation)

A method of isolating soluble pancreatic islet antigen employs extraction with a non-ionic detergent and fractionation on a gel filtration column. Fractions are screened for high immunoreactivity with diabetic serum which is positive for ICA immunofluorescence when tested on tissue sections of a pan ...


10
Margo P Cohen, Clyde W Shearman: Long-acting and controlled release formulations of 2-[(3-chlorophenyl) amino] phenylacetic acid. Glycadia, February 24, 2015: US08962020

Formulation of long-acting and controlled release preparations of 2-[(3-chlorophenyl)amino] phenylacetic acid (23CPPA) are disclosed. Long-acting preparations comprise a slow-release formulation coated onto a pharmaceutical composition containing 23CPPA, protect against gastric irritation, slow 23CP ...